A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337
NCT ID: NCT03382756
Last Updated: 2017-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2017-10-12
2017-11-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sixteen male subjects are divided into two groups. A group of subjects are administered a single oral dose of CKD-337 after ingesting high fat meal and the other take same investigational product (IP) in fasting condition. Then their blood is drawn on a fixed schedule to analyse bioavailability of CKD-337.
Finishing the first treatment period, the two groups switch food conditions and initiate the second period. The group of people that were administered CKD-337 with food are then dosed the same IP in fasting condition, and the other group undergo vice versa.
Each treatment period was separated by a washout period of at least 7 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition
Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition
High fat diet
A diet consisting of more than 900kcal and 35% of fat
CKD-337
Test Drug
Group B
Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition
Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition
High fat diet
A diet consisting of more than 900kcal and 35% of fat
CKD-337
Test Drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High fat diet
A diet consisting of more than 900kcal and 35% of fat
CKD-337
Test Drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index between 17.5 and 30.5 kg/m², body weight more than 55kg
3. Subject who doesn't have chronic disease, pathological symptoms or findings
4. Subject who is suitable for the clinical trial determined by laboratory tests(serum test, hematology test, blood chemistry, urinalysis test etc.), Vital Sign, ECG test at the time of screening
5. Subject who fully understand the clinical trial after in-depth explanation, decide to join the clinical trials and sign on an inform consent from willingly.
Exclusion Criteria
* Gallbladder disease including cholelithiasis, severe hepatic impairment
* Acute/chronic pancreatitis due to hypertriglyceridemia
* Pulmonary embolism or interstitial lung disease
* Genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
* Hypoalbuminemia
* Alcoholics
* Predisposition to rhabdomyolysis
2. Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption
3. Subject who has hypersensitivity to the drugs containing choline fenofibrate, fenofibrate or atorvastatin, or other drugs such as aspirin, fenofibrate series, antibiotics
4. Subject who has the following clinical significant findings in the EKG at the time of screening
* QTc(Q-T interval corrected for heart rate) \> 450ms
* PR interval(The interval between the beginning of the P wave and the beginning of the QRS complex in ECG) \> 200msec
* QRS duration(The duration of the QRS wave in ECG) \> 120msec
5. Subject whose results of the clinical laboratory tests are included in the following categories
* CPK(Creatinine Phospho-Kinase) \> 2x upper limit of normal range
* Liver function test (AST;Aspartate Transaminase, ALT;Alanine Transaminase, ALP;Alkaline phosphatase, Total bilirubin, γ-GT;Gamma-Glutamyl Transferase) \> 2 x upper limit of normal range
* eGFR(Estimated Glomerular Filtration Rate) \< 60 mL/min/1.73m² Calculated by MDRD(Modification of Diet in Renal Disease)
6. Systolic blood pressure ≥ 160mmHg(millimeter of mercury) or ≤ 100mmHg(millimeter of mercury) , Diastolic blood pressure ≥ 95mmHg(millimeter of mercury) or ≤ 60mmHg(millimeter of mercury) at the time of screening
7. History of drug abuse or a positive reaction for drug abuse examined by urinalysis at the time of screening
8. Subject who took medicines that are known to significantly induce or inhibit drug metabolizing enzymes, including barbiturates, within 30 days prior to the first dose of medication
9. Those who has experienced photoallergy or phototoxicity during treatment with fibrates or ketoprofen
10. Subject who took ETC(Ethical Drug), oriental medicine within 2 weeks and OTC(Over-the-counter Drug), vitamin within 10 days prior to the first dose of medication
11. Subject who took the medication involved in other clinical trials within 3 months prior to the first dose of medication
12. Subject who donated whole conducted blood donation within 2 months or component blood donation or blood transfusion within 1 month prior to the first dose of medication
13. Subject who drinks alcohol more than 21 units per a week (1unit=10g of pure alcohol) continuously within 6 month prior to the first dose of medication or Who can not stop drinking alcohol during the clinical trial
14. Smoker(\> 10 cigarettes/day) for the last 3 months or who can not stop smoking during the clinical trial
15. Subject who consumed food containing grapefruit within 48 hours prior to the first dose of medication or who can not stop consumption it until EOS(End of study)
16. Subject who consumed food containing caffeine(e.g. coffee, green tea etc.) within 24 hours prior to the first dose of medication or who can not stop consumption it until discharge
17. Subject who do not use a reliable contraception or who plans a pregnancy during the clinical trial
18. Subject who has unsuitable conditions decided by investigator's judgement including clinical laboratory result
19 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min Kyu Park, Professor
Role: PRINCIPAL_INVESTIGATOR
Dong-A University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dong-A University Hospital
Busan, Seo-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
146FDI17001
Identifier Type: -
Identifier Source: org_study_id